Variation in CDKAL1 Gene Is Associated With Therapeutic Response to Sulphonylureas

• DOI: 10.33549/physiolres.932228
• Publication Date: 2020-04-04T08:58:41Z
• Authors: Z. SCHRONER; M. JAVORSKÝ; J. HALUŠKOVÁ; L. KLIMČÁKOVÁ; E. BABJAKOVÁ; M. FABIANOVÁ; E. SLABÁ; M. KOZÁROVÁ; I. TKÁČ
• Keywords: Blood Glucose; Male; 0301 basic medicine; tRNA Methyltransferases; Genotype; Genetic Variation; Cyclin-Dependent Kinase 5; Middle Aged; Metformin; 3. Good health; 03 medical and health sciences; Sulfonylurea Compounds; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Female; Aged

The aim of the present pilot pharmacogenetic study was to analyse quantitative effects sulphonylurea treatment in addition metformin on parameters glycemic control with respect CDKAL1 genotypes patients type 2 diabetes. Effect 6-month therapy according evaluated 101 diabetes who failed achieve monotherapy. rs7756992 polymorphism determined by melting curve analysis small amplicon following real-time PCR. After fasting plasma glucose (FPG) levels were significantly different (p=0.045) among three genotype groups (AA: n=49; AG: n=36; GG: n=16). In a dominant genetic model, carriers G-allele (AG+GG, n=52) achieved lower FPG comparison AA (6.90±1.08 vs. 7.48±1.12 mmol/l, p=0.013). Consequently, adjusted ΔFPG higher AG+GG compared group (1.48±1.51 1.02±1.33 p=0.022). Similar trend observed for HbA1c levels, but difference between did not reach level statistical significance. Relatively number included is limitation study. conclusion, our results suggest that magnitude reduction after related variation CDKAL1.